FORMULATION AND EVALUATION OF A TOPICAL GEL CONTAINING MINOXIDIL AND TOFACITINIB CITRATE FOR ALOPECIA AREATA

BHUVANESHWARI SHARANNAVAR; MONALI BHAGAT AMONKAR; POONAM INAMDAR; MRUNALINI KULKARNI

doi:10.22159/ijap.2023v15i5.45798

Authors

BHUVANESHWARI SHARANNAVAR Department of Pharmaceutical Quality Assurance, Kles College of Pharmacy Belagavi, Kle Academy of Higher Education And Research, Belagavi-590010, Karnataka, India
MONALI BHAGAT AMONKAR Department of Pharmaceutical Quality Assurance, Kles College of Pharmacy Belagavi, Kle Academy of Higher Education And Research, Belagavi-590010, Karnataka, India
POONAM INAMDAR Department of Pharmaceutical Chemistry, School of Pharmacy, Vishwakarma University, Pune-411048 Maharashtra, India
MRUNALINI KULKARNI Department of Pharmaceutical Chemistry, School of Pharmacy, Vishwakarma University, Pune-411048 Maharashtra, India

DOI:

https://doi.org/10.22159/ijap.2023v15i5.45798

Keywords:

Minoxidil, Tofacitinib citrate, Alopecia areata, Topical gel

Abstract

Objective: The objective of the present study is to formulate and evaluate a topical gel containing Minoxidil and Tofacitinib citrate for alopecia areata.

Methods: Six gels were formulated using the direct-dispersion method by using polymers in the ratio of Carbopol 934: HPMC and Carbopol 934: HPC in three different concentrations each. All the prepared gels were then characterized for its drug content, pH, Rheological measurement, Spreadibility, skin adhesion study, In vitro drug release, Ex-vivo skin permeation study and stability studies.

Results: All the six formulations were evaluated for various parameters such as pH, viscosity, spreadibility, and drug content and in vitro drug release. The pH of all the formulations was in the range of 6.3-6.8 which was optimum for the skin. As the concentration of the polymer increased the viscosity also increased, F6 had the highest viscosity among all of 1082 cps. F5 had the highest spreadibility of 4.3±0.15 cm and the drug content of all ranged between 88-96% of Minoxidil and 86-97% for Tofacitinib citrate with F5 giving the best result drug release across a cellulose membrane for a period 8 h of 94.22±0.19% for Minoxidil and 93.62±0.49% for Tofacitinib citrate. Formulation F2 and F5 were subjected to skin adhesion studies by the use of wistar rat skin with F5 giving the highest bioadhesion of 108 g/cm2. Formulation F5 was selected as an optimized formulation among the six as it gave the best results for all the parameters. Then the optimized formulation was subjected to an ex-vivo permeation study for a period of 8 h and by using wistar rat skin as a permeation barrier and the drug release for Minoxidil and Tofacitinib citrate was found to be 71.94±0.78% and 69.49±0.47%. The stability study was carried out for two months at accelerated condition i.e., 40 °C±2 °C/75±5% RH proved that the formulated gel was Stable.

Conclusion: The formulated topical gel containing Minoxidil and Tofacitinib citrate were found to be a promising approach for the treatment of alopecia areata.

Downloads

Download data is not yet available.

References

Mohan A, Khan MA, Chandra S. Advance approaches in alopecia. Pharm Biol Eval. 2017;4(3):135-40. doi: 10.26510/2394-0859.pbe.2017.21.

Kumar P, Singh S, Jindal D, Handa V, Bilonia J. Formulation and evaluation of minoxidil gel using acrylamide/sodium acryloyl-dimethyl taurate copolymer for alopecia areata. Int J Pharm Sci Drug Res. 2018;10(1):1-6.

Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S. Minoxidil use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012;6(2):130-6. doi: 10.2174/187221312800166859, PMID 22409453.

Iorizzo M, Tosti A. Emerging drugs for alopecia areata: JAK inhibitors. Expert Opin Emerg Drugs. 2018;23(1):77-81. doi: 10.1080/14728214.2018.1444750, PMID 29466675.

Tegtmeyer K, Zhao J, Maloney NJ, Atassi G, Beestrum M, Lio PA. Off-label studies on tofacitinib in dermatology: a review. J Dermatol Treat. 2021;32(4):399-409. doi: 10.1080/09546634.2019.1673877.

Wagner L, Kenreigh C. Minoxidil X pharm: the comprehensive pharmacology reference. Elseveir. New York; 2007. p. 1-5.

Reddy MS, Mutalik S, Rao GV. Preparation and evaluation of minoxidil gels for topical application in alopecia. Indian J Pharm Sci. 2006;68(4):432-6. doi: 10.4103/0250-474X.27813.

Wambier CG, Craiglow BG, King BA. Combination tofacitinib and oral minoxidil treatment for severe alopecia areata. J Am Acad Dermatol. 2021;85(3):743-5. doi: 10.1016/j.jaad.2019.08.080.

Kaur L, Kumar Guleri T. Topical gel: a recent approach for novel drug delivery. Asian J Biomed Pharm Sci. 2013;3(17):1-5.

Patzelt A, Lademann J. Drug delivery to hair follicles. Expert Opin Drug Deliv. 2013;10(6):787-97. doi: 10.1517/17425247.2013.776038, PMID 23530745.

Parhi R, Terapalli B, Teja B. Formulation and in vitro evaluation of Minoxidil topical gel. Turk J Pharm Sci. 2014;11(2):153-62.

Usmania Bilandi A, Kataria MK. Formulation and evaluation of minoxidil emulgel for androgenic alopecia. Indo Am J Pharm Sci. 2016;3(12):1593-610.

Meera CS, Ajinkya SN, Sawant SD. Trandermal drug delivery system with major emphasis on transdermal patches. J Pharm Res Int. 2010;3(10):2537-4.

Gupta S, Shahi S, Tadwee I, Zadbuke N, Tribhuwan S, Sonawane U. Enhanced topical formulation of minoxidil gel for alopecia condition. Int J Pharm Res Allied Sci. 2011;1(1):41-7.

Sunitha S. Formulation and evaluation of minoxidil gels for topical application. IJPR. 2014;3(1):7-10.

Patel VM, Prajapati BG, Patel HV, Patel KM. Mucoadhesive bilayer tablets of propranolol hydrochloride. AAPS PharmSciTech. 2007;8(3):E203-8. doi: 10.1208/pt0803077.

Rao S, Matlonia A, Seth N, Gill NS. Development and characterization of minoxidil emulgel for topical drug delivery. Int J Univers Pharm Biosci. 2016;5(4):224-35.

Csoka I, Csanyi E, Zapantis G, Nagy E, Feher Kiss A, Horvath G. In vitro and in vivo percutaneous absorption of topical dosage forms: case studies. Int J Pharm. 2005;291(1-2):11-9. doi: 10.1016/j.ijpharm.2004.07.038, PMID 15707727.